Equities

Equillium Inc

Equillium Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.87
  • Today's Change0.02 / 2.35%
  • Shares traded70.08k
  • 1 Year change+8.26%
  • Beta1.8616
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 4 analysts offering 12 month price targets for Equillium Inc have a median target of 7.00, with a high estimate of 8.00 and a low estimate of 5.00. The median estimate represents a 704.60% increase from the last price of 0.87.
High819.5%8.00
Med704.6%7.00
Low474.7%5.00

Earnings history & estimates in USD

On Aug 08, 2024, Equillium Inc reported 2nd quarter 2024 earnings of 0.01 per share. This result exceeded the -0.150 consensus loss of the 4 analysts covering the company and outperformed last year's 2nd quarter results by 0.11.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+4.03%
Equillium Inc reported annual 2023 losses of -0.37 per share on Mar 25, 2024.
Average growth rate+12.88%
More ▼

Revenue history & estimates in USD

Equillium, Inc. had 2nd quarter 2024 revenues of 13.85m. This bettered the 6.33m consensus of the 4 analysts covering the company. This was 56.02% above the prior year's 2nd quarter results.
Average growth rate+11.68%
Equillium, Inc. had revenues for the full year 2023 of 36.08m. This was 128.97% above the prior year's results.
Average growth rate+42.99%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.